Tag:
Justice Department
Latest Headlines
Latest Headlines
Former exec indicted, accused of selling adulterated devices
The former head of Zinnanti Surgical Design is accused of selling non-sterile devices to hospitals and faces up to three years in prison and a $250,000 fine.
Biomet to cough up almost $23M to settle bribery charges
Another devicemaker has been ensnared in a Foreign Corrupt Practices Act probe.
Pharma fraud fills feds' coffers
The Justice Department says it secured more than $3 billion in settlements and judgments in civil cases involving fraud against the government in the fiscal year that ended Sept. 30--and the bulk of
Study: Bigger fines needed to ward off marketing misbehavior
Do government probes deter bad pharma behavior? Researchers delved into the Neurontin off-label marketing settlement to find out. Their conclusion: Off-label prescribing continued apace after federal
Justice subpoenas Merck on drug marketing
Merck ( $MRK ) has been subpoenaed for information about the marketing of several of its drugs, the company disclosed in a securities filing. The Justice Department has asked for information on
Feds probe Cephalon on Provigil, Nuvigil promos
The Justice Department isn't just interested in Cephalon's Treanda operations. It's also looking at the drugmaker's wakefulness meds Nuvigil and Provigil. Cephalon ( $CEPH ) said the feds issued a
J&J's Scios to plead guilty, pay $85M in Natrecor case
Johnson & Johnson's ( $JNJ ) legion of legal problems is one less strong. The company agreed to pay $85 million and plead guilty to a misdemeanor charge in a Justice Department probe of its
Teva's second hep C lawsuit goes to trial
Teva Pharmaceutical Industries ( $TEVA ) is in court this week, fighting its second lawsuit claiming that anesthetic vials sold by the company caused patients to develop hepatitis C. The company faces
Witness taped Baxter lawyer's payment offer
It's not a good time for drugmakers to be connected with "questionable payments" in foreign countries. The Justice Department is on an enforcement tear, probing pharma companies for potential
J&J, feds reach deal on one Risperdal charge
Johnson & Johnson ( $JNJ ) has come to terms with the Justice Department on one Risperdal marketing charge. It's a single misdemeanor, stemming from a long-running investigation of allegations that
